Inflammatory Control of Antidepressant Efficacy: a Pharmaco-epigenetic Approach

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

January 14, 2025

Conditions
Mood DisordersMajor Depressive Disorder
Interventions
OTHER

Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management

All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.

Trial Locations (1)

20132

RECRUITING

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER